Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review.

[1]  J. Gore,et al.  Quality Indicators for Bladder Cancer Services: A Collaborative Review. , 2020, European urology.

[2]  S. Shariat,et al.  Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis , 2020, International Journal of Clinical Oncology.

[3]  S. Shariat,et al.  Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. , 2020, Current opinion in urology.

[4]  S. Shariat,et al.  The promise and challenges of neoadjuvant immunotherapy in the management of non‐metastatic muscle‐invasive bladder cancer , 2020, BJU international.

[5]  S. Shariat,et al.  Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. , 2019, Clinical genitourinary cancer.

[6]  M. Babjuk,et al.  EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. , 2019, European urology.

[7]  M. Milowsky,et al.  Perioperative systemic therapy for bladder cancer , 2019, Current opinion in urology.

[8]  Y. Lotan,et al.  Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts , 2019, International journal of molecular sciences.

[9]  T. Dorff,et al.  Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. , 2019, Urologic oncology.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  B. Rini,et al.  Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. , 2018, Urologic oncology.

[12]  S. Shariat,et al.  Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. , 2018, Urologic oncology.

[13]  R. Autorino,et al.  Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. , 2018, European urology oncology.

[14]  S. Crabb,et al.  The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study , 2018, Bladder cancer.

[15]  G. Scagliotti,et al.  Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. , 2017, Cancer treatment reviews.

[16]  O. Buisán,et al.  Low Pretreatment Neutrophil‐to‐Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer , 2017, Clinical genitourinary cancer.

[17]  Z. Symon,et al.  Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  T. Klatte,et al.  Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. , 2016, Urologic oncology.

[19]  W. Hwang,et al.  Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710 , 2016, Cancer.

[20]  M. Babjuk,et al.  The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. , 2016, European urology focus.

[21]  J. Knox,et al.  Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. , 2015, Clinical genitourinary cancer.

[22]  S. Crabb,et al.  Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract , 2014, British Journal of Cancer.

[23]  S. Barni,et al.  Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. , 2014, European urology.

[24]  Zhoujun Shen,et al.  Inflammatory Pathways as Promising Targets to Increase Chemotherapy Response in Bladder Cancer , 2012, Mediators of inflammation.

[25]  R. Wahlqvist,et al.  Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.

[26]  Yair Lotan,et al.  Statistical consideration for clinical biomarker research in bladder cancer. , 2010, Urologic oncology.

[27]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[28]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[29]  F. Montorsi,et al.  Nomograms for bladder cancer. , 2008, European urology.

[30]  K. Bensalah,et al.  Challenges of cancer biomarker profiling. , 2007, European urology.

[31]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[32]  Ö. Yaman,et al.  The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using neoadjuvant M‐VEC chemotherapy , 1999, BJU international.

[33]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.